CoreRx on Facebook CoreRx on Twitter CoreRx on LinkedIn

CoreRx, a contract formulator and manufacturer of complex pharmaceutical products, announced that the Company has completed a placement of Series A Preferred Stock with Signet Healthcare Partners.

Company to Invest Approximately $2 Million, Continues to Increase Workforce

Monday, 03 February 2014 11:05

Spotlight on Brian McMillan, M.S.Pharm.

Brian McMillan, V.P. of Formulations is a valuable asset to CoreRx. He brings many years of experience and talent and is a driving force in the success of CoreRx. With that aside, it's easy for any conversation with Brian to gravitate to his beloved "Buckeyes." It's very clear that Brian loves his roots. As an Ohio State University (OSU) alumni, he holds the school close to his heart. Based on an article posted in 2012, it's clear the feelings are mutual. CoreRx is honored to share an article posted by OSU where the spotlight is on Brian and his past and future accomplishments. We're happy to report that Brian did earn his M.S. in Pharmaceutical Chemistry from the University of Florida in 2013 and continues his relationship teaching at the University of South Florida, College of Pharmacy. We're fortunate at CoreRx to have such talented and skilled professionals among us.

Read the OSU article here:

Tuesday, 24 September 2013 08:47

CoreRx Strengthens Team with Key Hires

CoreRx Strengthens Project Management Team and Formulation Development Expertise with Key Hires

Companies to Invest in New Facility, Increase Workforce

Key members of our management team attended the Controlled Release Society (CRS) meeting in Hawaii in July. The conference was a huge success for CoreRx and we we're also proud to take part by submitting a poster. We have attached it here for those who would like to review.

We are planning to attend and exhibit at upcoming conferences including Contract Pharma in September and the AAPS in November. We are looking forward to seeing you there and if you would like to setup a meeting, please let us know at  


 Co-Processed Excipients: A Strategy for Reducing Risk in Early Dosage Form Development


Tampa, FL (June 24, 2013) – The University of South Florida College of Pharmacy and CoreRx, Inc., a research-based drug development firm, received a $200,000 award from the Florida High Tech Corridor to bolster the training needed to prepare students for innovation and technology in the pharmaceutical industry.

Company to Invest Approximately $2 Million, Increase Workforce

Page 1 of 6

source logos